FDA-approved1,2Evidence: Smaller human trialsCancer

Lutetium Lu 177 dotatate1

Also called Lutathera1,2

Key takeaway

Lutetium Lu 177 dotatate is a radioactive drug made of a cyclic somatostatin-like peptide linked to the radioactive metal lutetium-177. It is the active ingredient in Lutathera.1,2 It is approved for adults and children 12 and older with somatostatin receptor-positive neuroendocrine tumors of the stomach, intestines and pancreas.1 In the randomized NETTER-1 trial of 229 patients described in the label, the disease progressed or the patient died in 23% of those given Lutathera and 69% of those given octreotide alone, but final overall survival did not differ significantly.1

Lutetium Lu 177 dotatate at a glance

What it isA radiolabeled somatostatin analogue: a cyclic peptide bound through a chelator to lutetium-177, which emits beta radiation, according to the Lutathera label.1
FDA statusFDA-approved. Drugs@FDA lists Lutathera, NDA 208700, with an original approval date of January 26, 2018, and a second product, Bexlutry, NDA 218525, approved September 14, 2026. The cited label has no boxed warning.1,2,3
Human evidenceOne randomized, open-label, active-controlled trial (NETTER-1) in 229 patients with midgut carcinoid tumors, described in the label.1
Evidence strengthSmaller controlled human trials. The cited sources include randomized or otherwise controlled human trials that are fully reported in a journal article or in posted registry results, but none meets the large-trial rule. How this label is assigned

What is lutetium Lu 177 dotatate?

It is a radioactive peptide drug: an eight-amino-acid cyclic peptide related to somatostatin, linked by the chelator DOTA to lutetium-177, according to the label.1

In the United States it is the active ingredient of Lutathera, approved under NDA 208700, and of Bexlutry, approved under NDA 218525, according to Drugs@FDA.2,3

How does lutetium Lu 177 dotatate work?

The label states that it binds most strongly to subtype 2 somatostatin receptors and is taken up into cells that carry them, including tumor cells, where beta radiation from lutetium-177 damages those cells and their neighbours.1

What do human studies show?

NETTER-1, a randomized, open-label trial described in the label, compared Lutathera plus long-acting octreotide with long-acting octreotide alone in 229 patients with progressive, well-differentiated midgut carcinoid tumors.1

Progression or death occurred in 27 of 116 patients (23%) given Lutathera and 78 of 113 (69%) given octreotide alone, and tumors shrank in 13% versus 4%. At the final analysis, overall survival did not differ significantly between the groups, according to the label.1

What the evidence base contains

  • Controlled human trial NETTER-1 (NCT01578239): a randomized, open-label, active-controlled trial in 229 patients with progressive midgut carcinoid tumors, comparing Lutathera plus octreotide with octreotide alone, described in the label.1

Evidence-strength label: Smaller controlled human trials. How this label is assigned

Is lutetium Lu 177 dotatate FDA-approved?

Yes. Drugs@FDA lists Lutathera, application NDA 208700, with an original approval date of January 26, 2018, and Bexlutry, application NDA 218525, approved September 14, 2026.2,3

The Lutathera label cited here (DailyMed SPL version 12, published January 16, 2026) states that it is indicated for adult and pediatric patients 12 years and older with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.1

The label has no boxed warning. Its warnings include radiation exposure, suppression of blood cell production, later myelodysplastic syndrome and leukemia, and kidney toxicity.1

HHS’s October 30, 2026 draft enforcement-discretion policy lists six peptides in its Appendix A: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. Lutetium Lu 177 dotatate is not among them.4,5

Timeline

  1. FDA approves Lutathera, NDA 208700, according to Drugs@FDA.2
  2. DailyMed publishes the Lutathera label version cited on this page.1
  3. FDA approves Bexlutry, NDA 218525, a second lutetium Lu 177 dotatate product, according to Drugs@FDA.3

What is still unknown?

Whether it lengthens survival: in NETTER-1, the final overall survival analysis showed no statistically significant difference from octreotide alone.1

PeptideScanner reports what the cited sources say. It is not medical advice and does not recommend using, buying or dosing any substance. Read the full disclaimer.

Go deeper

Records, reviews and history

Everything PeptideScanner has collected for Lutetium Lu 177 dotatate: reviews, official-source readings, registry and literature records, and every change to this profile.

What the trial and literature lists cover. The trials and papers listed for Lutetium Lu 177 dotatate are a bounded selection, not every registration or paper about Lutetium Lu 177 dotatate. For the years before Lutetium Lu 177 dotatate was added, PeptideScanner took at most 25 ClinicalTrials.gov registrations that list Lutetium Lu 177 dotatate as an intervention: trials with posted results first, then later-phase trials, then the most recently updated. It also took at most 25 PubMed papers that name Lutetium Lu 177 dotatate in the title: randomized controlled trials, clinical trials, meta-analyses, systematic reviews and reviews first, then the most recent. Records that also named another tracked peptide, or that failed the publication checks, were left out. A daily check adds newly updated registrations and newly indexed papers that pass the same checks. How records are selected.

Status brief and reviewed-evidence summary

Evidence summary

What the cited records show

What is its status in the cited records?

FDA-approved as Lutathera for gastroenteropancreatic neuroendocrine tumors. In a randomized trial of 229 patients described in the label, Lutathera delayed progression compared with octreotide alone, but final overall survival did not differ significantly.↗↗

Status sources checked through November 15, 2026. See status sources and coverage →

Research records

Explore this profile’s cited source records →

An editorial human-evidence summary has not yet been published.

Explore status sources, recent additions, and coverage gaps

Living status brief

What is the current status of Lutetium Lu 177 dotatate?

FDA-approved as Lutathera for gastroenteropancreatic neuroendocrine tumors. In a randomized trial of 229 patients described in the label, Lutathera delayed progression compared with octreotide alone, but final overall survival did not differ significantly.↗↗

The cited status sources were checked through November 15, 2026. This answer changes only through the profile’s visible version and correction history.

Evidence present

What records are connected here?

Evidence lanes
3
Source years
6
Drugs@FDA applications
3

These are counts in PeptideScanner’s selected public collection, not measures of research quality, medical relevance, safety, or effectiveness.

Latest source-dated record

What changed most recently at a cited source?

Clinical trials · source date November 16, 2026

ClinicalTrials.gov record NCT05278208↗Added to PeptideScanner November 16, 2026

Coverage gaps

What remains unknown or unsupported?

PeptideScanner currently has no selected safety records connected to this profile. That is a collection gap, not evidence that no such records exist.

PeptideScanner does not infer an answer where the cited records do not provide one. Open the source-linked records below to inspect their scope and limits.

Explore the Evidence Map and record counts

Evidence Map v1

What kinds of records connect to Lutetium Lu 177 dotatate?

Compare collection coverage →

This map describes PeptideScanner’s selected, source-linked collection. It is not an evidence grade and does not establish research quality, safety, effectiveness, or medical relevance.

41Selected dated records
46Connected citations
6Populated source years2018–2026
3/4Record lanes present

Registered human studies

Trial composition

27 of 27 selected trial records include at least one phase value; 27 of 27 include a status value in the retained structured contract.

PhasesPhase 2 20Phase 1 7Phase 3 4Phase 4 1
Status at observationRecruiting 13Active, not recruiting 9Completed 4Not yet recruiting 1

PubMed bibliography

Publication composition

10 of 10 selected PubMed records include attributed title, venue, publication date, and publication-type fields.

Publication typesJournal Article 9Research Support, Non-U.S. Gov't 2Case Reports 1Clinical Trial, Phase I 1Clinical Trial, Phase II 1Letter 1Multicenter Study 1Randomized Controlled Trial 1Review 1

Regulatory and publication surfaces

What is structurally connected?

Drugs@FDA applications
3
FDA Federal Register documents
1
DailyMed SPL versions
0
Canonical profile
Published
Profile structured data
Published
Linked dated records
41

Application counts reflect exact reviewed ingredient connections; Federal Register counts reflect exact reviewed peptide-name matches; DailyMed counts reflect listed SPL versions with retained ZIP receipts. “Published” describes this page’s indexing surface, not the state of scientific evidence.

Profile publication history and record counts
Source records by collection · 41 dated records

Research hub

Explore the Lutetium Lu 177 dotatate evidence record

Open all 41 records →
41Dated records
3Evidence types
41Cited public sources
6Source years

Change ledger

Recently changed for Lutetium Lu 177 dotatate

Open all 42 events →

PeptideScanner change dates and cited source dates stay separate. These entries report collection or version activity, not a ranking of importance.

Record added

ClinicalTrials.gov record NCT01578239

PeptideScanner retained ClinicalTrials.gov record NCT01578239 at 2026-11-16T01:36:36.861Z. Its registry update date was 2022-04-04, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.

PeptideScanner change date
November 16, 2026
Cited source date
April 4, 2022
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT03325816

PeptideScanner retained ClinicalTrials.gov record NCT03325816 at 2026-11-16T01:36:36.861Z. Its registry update date was 2021-03-16, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.

PeptideScanner change date
November 16, 2026
Cited source date
March 16, 2021
Evidence lane
Clinical trials
Record added

ClinicalTrials.gov record NCT03457948

PeptideScanner retained ClinicalTrials.gov record NCT03457948 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-08-28, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.

PeptideScanner change date
November 16, 2026
Cited source date
August 28, 2026
Evidence lane
Clinical trials

Official-source collections

Source records for Lutetium Lu 177 dotatate

Open the full research atlas →
PubMed10

10 with attributed title, venue, publication-date, and type metadata.

  1. FAERS based pharmacovigilance study and network pharmacology analysis of Lutathera and Pluvicto.Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine · 2026 04 01
  2. Hematological toxicities with Lutathera® for neuroendocrine neoplasms: post-marketing surveillance data from the US-FDA.Endocrine · 2024 06 07
  3. Peptide radionuclide radiation therapy with Lutathera in multirecurrent nonanaplastic meningiomas: antitumoral activity study by growth rate analysis.Journal of neuro-oncology · 2024 03 07
Explore all selected literature →
ClinicalTrials.gov27

0 public history versions across these dated registry records; status labels apply only to each cited observation.

  1. NCT05278208Registry update November 16, 2026 · current at observation
  2. NCT04234568Registry update November 13, 2026 · current at observation
  3. NCT04665739Registry update November 12, 2026 · current at observation
Explore all selected trial records →Explore all public record history →

Coverage by source year

Selected records span January 26, 2018 to November 16, 2026. These dates come from selected source records and PubMed metadata, not a complete or continuous timeline of research, safety, approval, or effectiveness.

Continue exploring

Profiles with overlapping source-year coverage

Open the research atlas →

These links are based only on overlapping years and evidence lanes in PeptideScanner’s selected records. They do not imply that the peptides are medically or scientifically similar.

Organizations and trial records named in cited sources

Organizations named in cited records

  • U.S. National Library of Medicine1
  • U.S. Food and Drug Administration2,3
  • U.S. Department of Health and Human Services4
Dated updates connected to this profile · 41

Updates connected to this profile

Open the full cross-source timeline →
  1. Clinical trials

    ClinicalTrials.gov record NCT05278208↗

    PeptideScanner retained ClinicalTrials.gov record NCT05278208 at 2026-11-16T13:28:59.838Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.↗

  2. Clinical trials

    ClinicalTrials.gov record NCT04234568↗

    PeptideScanner retained ClinicalTrials.gov record NCT04234568 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-11-13, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.↗

  3. Clinical trials

    ClinicalTrials.gov record NCT04665739↗

    PeptideScanner retained ClinicalTrials.gov record NCT04665739 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.↗

  4. Clinical trials

    ClinicalTrials.gov record NCT04750954↗

    PeptideScanner retained ClinicalTrials.gov record NCT04750954 at 2026-11-16T02:15:32.969Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.↗

  5. Clinical trials

    ClinicalTrials.gov record NCT05178693↗

    PeptideScanner retained ClinicalTrials.gov record NCT05178693 at 2026-11-16T02:15:32.969Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.↗

  6. Clinical trials

    ClinicalTrials.gov record NCT05691465↗

    PeptideScanner retained ClinicalTrials.gov record NCT05691465 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.↗

  7. Clinical trials

    ClinicalTrials.gov record NCT05773274↗

    PeptideScanner retained ClinicalTrials.gov record NCT05773274 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.↗

  8. Clinical trials

    ClinicalTrials.gov record NCT06955169↗

    PeptideScanner retained ClinicalTrials.gov record NCT06955169 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-11-09, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.↗

  9. Literature metadata

    Clinical Pharmacokinetics of Radiopharmaceuticals from SPECT/CT Image Acquisition by Contouring in Patients with Gastroenteropancreatic Neuroendocrine Tumors: Lu-177 DOTATATE (Lutathera®) Case.↗

    PubMed lists PMID 37184824 in European journal of drug metabolism and pharmacokinetics as Journal Article, with publication-date metadata of 2023-05-15 (day precision). PeptideScanner associated the retained record with the identity slug lutetium-lu-177-dotatate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  10. Literature metadata

    177 Lu-DOTATATE (Lutathera) Therapy in 68 Ga-DOTATATE PET/CT-Negative Liver Metastases of a Neuroendocrine Tumor.↗

    PubMed lists PMID 37883194 in Clinical nuclear medicine as Case Reports, Journal Article, with publication-date metadata of 2023-10-23 (day precision). PeptideScanner associated the retained record with the identity slug lutetium-lu-177-dotatate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

  11. Clinical trials

    ClinicalTrials.gov record NCT07910760↗

    PeptideScanner retained ClinicalTrials.gov record NCT07910760 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-11-02, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.↗

  12. Literature metadata

    Peptide radionuclide radiation therapy with Lutathera in multirecurrent nonanaplastic meningiomas: antitumoral activity study by growth rate analysis.↗

    PubMed lists PMID 38451361 in Journal of neuro-oncology as Journal Article, with publication-date metadata of 2024-03-07 (day precision). PeptideScanner associated the retained record with the identity slug lutetium-lu-177-dotatate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗

Citations

Sources

Coverage and sources →

Numbered markers in the text point here. Each link opens the original public record.

  1. 1
    LUTATHERA (lutetium Lu 177 dotatate) injection · SPL version 12 · published 2026-01-16 ↗

    DailyMed · U.S. National Library of Medicine · Official source · Source checked November 15, 2026

  2. 2
    Drugs@FDA: LUTATHERA (lutetium Lu-177 dotatate), NDA 208700 · original approval January 26, 2018 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 15, 2026

  3. 3
    Drugs@FDA: BEXLUTRY (lutetium Lu-177 dotatate), NDA 218525 · original approval September 14, 2026 ↗

    U.S. Food and Drug Administration · Official source · Source checked November 15, 2026

  4. 4
    Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗

    Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  5. 5
    HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

    U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026